Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2000595 | 1.00 | USP2 (0.37) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL2789359 | 1.00 | USP2 (0.37) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL27550874 | 1.00 | USP2 (0.37) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL5859311 | 0.83 | PDE4A (0.41) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL16798768 | 0.83 | PDE4A (0.41) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL29162767 | 0.83 | PDE4A (0.41) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL29020598 | 0.82 | LMNA (0.46) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL19717486 | 0.82 | — | — | |
| SCHEMBL17260872 | 0.82 | USP2 (0.35) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL941684 | 0.81 | LMNA (0.36) | USP2SLCO1B1LMNAL3MBTL1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3423457-A1 | PROCESS FOR THE PREPARATION OF AN ANTIBODY-RIFAMYCIN CONJUGATE | H. Hoffnabb-La Roche Ag (CH) | 2019-01-09 | — | — | EP | disclosed |
| EP-3226911-A1 | ANTI-STAPHYLOCOCCUS AUREUS ANTIBODY RIFAMYCIN CONJUGATES AND USES THEREOF | F.HOFFMANN-LA ROCHE AG (CH) | 2017-10-11 | — | — | EP | disclosed |
| WO-2016090038-A1 | ANTI-STAPHYLOCOCCUS AUREUS ANTIBODY RIFAMYCIN CONJUGATES AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| EP-3004162-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | Genentech, Inc. (US) | 2016-04-13 | — | — | EP | disclosed |
| EP-3004161-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | Genentech, Inc. (US) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014194247-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | GENENTECH, INC. (US) | 2014-12-04 | — | — | WO | disclosed |
| WO-2014193722-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | GENENTECH, INC. (US) | 2014-12-04 | — | — | WO | disclosed |
| US-7528113-B2 | Method and composition for the treatment of adenoviral ocular infections | ADENOVIR PHARMA AB (SE) | 2009-05-05 | — | — | US | disclosed |
| EP-1231925-B1 | METHOD AND COMPOSITION FOR THE TREATMENT OF ADENOVIRAL OCULAR INFECTIONS | WADELL GOERAN (SE) | 2005-06-08 | — | — | EP | disclosed |
| US-20050080041-A1 | Method and composition for the treatment of adenoviral ocular infections | ADENOVIR PHARMA AB (SE) | 2005-04-14 | — | — | US | disclosed |
| EP-1231925-A1 | METHOD AND COMPOSITION FOR THE TREATMENT OF ADENOVIRAL OCULAR INFECTIONS | Wadell, Göran (SE) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001037846-A1 | METHOD AND COMPOSITION FOR THE TREATMENT OF ADENOVIRAL OCULAR INFECTIONS | WADELL GOERAN (SE) | 2001-05-31 | — | — | WO | disclosed |